OPO. G. Pyaterkina

O. G. Pyaterkina

*This is an algorithmically generated author record based on publicly available information.

O. G. Pyaterkina has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dynamics of lung function in patients with cystic fibrosis living in the Volga Federal District in 2017 and 2023

    by V.V. Shadrina, A.S. Sorokin, O.V. Kondratenko, E.A. Vasilyeva, M.G. Rybalkina, O.G. Pyaterkina, O.A. Karpova, O.I. Golubtsova, T.V. Simanova, M.V. Erzutova, et al.

    Cystic fibrosis (CF) is a severe hereditary disease that leads to decreased lung function. Objective. To assess the dynamics of lung function changes in CF patients living in the Volga Federal District (VFD) regions based on data from the 2017 and 2023 registries. Material and methods. Spirometry data from 375 patients from the 2017 CF patient registry and 451 patients from the 2023 registry were analyzed. Results. The median FEV1 data in VFD patients was 76.8% of the predicted value in 2017 and significantly increased to 95.3% of the predicted value in 2018. in 2023 (p<0.001). In 2017, FEV1 values in patients with CF in the Volga Federal District were not significantly different from those in the Russian Federation (75.5% of the predicted value), while in 2023, they were significantly higher than in patients in other regions of Russia (81.1% of the predicted value), p<0.001. FEV1 values increased significantly in patients from the Nizhny Novgorod Region, Orenburg Region, Perm Krai, the Republic of Tatarstan, and the Chuvash Republic. The median FVC in patients with CF from the Volga Federal District in 2017 was 85.1% of the predicted value and significantly increased to 94.0% of the predicted value in 2023 (p<0.01). In 2017, the FVC indicators in patients with CF in the Volga Federal District did not differ significantly from those in patients in the Russian Federation (86.0% of the predicted value), and in 2023 they were significantly higher than in patients in other regions of Russia (91.0% of the predicted value), p=0.037. The FVC indicators in 2023, compared with 2017, significantly increased in patients in the Nizhny Novgorod Region (p<0.001), Orenburg Region (p<0.001), Perm Krai (p=0.021), the Republic of Tatarstan (p=0.043), and the Chuvash Republic (p=0.003). In patients in the Samara Region, the indicators remained stable (p=0.331). Conclusions. FEV1 and FVC values in CF patients in both the Volga Federal District and the Russian Federation increased significantly in 2023 compared to 2017. Patient data from Volga Federal District regions where specialized CF centers were established were more informative, and patients had higher lung function values.

  • Open Access

    The effectiveness of a generic CFTR-modulator in a prolonged multicenter study

    by E. I. Kondratyeva, A. Yu. Voronkova, E. K. Zhekayte, V. N. Kovalev, A. V. Orlov, O. G. Pyaterkina, E. A. Ovsiannikova, M. G. Rybalkina, Е. И. Кондратьева, A. Ю. Воронкова, et al.

    Introduction. Prior to recent years, treatment of cystic fibrosis (CF) consisted primarily of symptom management. The pathogenetic therapy with CFTR modulators has emerged as a revolutionary method, supplying the capacity to correct the underlying CFTR chloride channel dysfunction. Aim. To evaluate the efficacy of the generic ivacaftor/tezacaftor/elexacaftor and ivacaftor Trileksa® in a group of patients with pediatric cystic fibrosis, who have been previously treated with branded CFTR modulator Trikafta®, over a 9-month period. Materials and methods. The Russian Cystic Fibrosis Patient Registry (RCFPR) data were analysed. A total of 156 subjects (82 girls (52.6%) and 74 boys (47.4%) aged 6 to 17 years) with a median age at treatment initiation Me (Q1; Q3) 12 (10; 14) were included in the study. Before starting the generic drug, all children received the brand-name drug. The median duration of treatment with the original drug was 25 (19; 30) months. Results. The median sweat test value achieved during treatment with the brand-name drug remained at the cutoff level of 64 (56; 81) mmol/L after 9 months of treatment with the generic drug (p1-4 = 0.93). The median FEV1 and FVC (%pred spirometry measurements) remained stable without negative changes overtime (FEV1 p1-4 = 0.40, FVC p1-4 = 0.70). The patients had significant changes in weight and height over the 9-month course of treatment. Adverse reactions to Trilexa therapy were rare, and the incidence was comparable with that observed for the generic drug. A slight increase in total bilirubin within reference ranges from 9.6 (7.4; 15.4) at baseline to 11.9 (8.9; 17.5) after 9 months was reported (p = 0.02) while the frequency of elevated liver function tests decreased from 5.2% to 3.2%. The number of patients with mental disorders increased: no depressive coditions were observed at treatment initiation, but after 9 months they were reported in 3.2% of patients. The percentage of patients with sleep disturbances increased from 1.3 to 3.8%, headaches from 3.8 to 6.4%, and fatigue from 4.7 to 6.4%. Conclusions. The generic Trileksa is not inferior to the brand-name drug, helps stabilize the achieved clinical and therapeutic outcomes and leads to further improvement in the course of the disease. It is safe, and well tolerated in patients. The long-term efficacy and safety of the drug must be monitored and continuously evaluated while on the market.

  • Regional experience in monitoring children with cystic fibrosis on targeted therapy in the Republic of Tatarstan within one international nonproprietary name

    by O.G. Pyaterkina, O.A. Karpova, G.R. Begieva, I.I. Zakirov, D.T. Shayapova, C.A. Bagauova

    Background. Due to the widespread use of targeted therapy drugs with various trade names in the treatment of cystic fibrosis, there is a need for a clinical evaluation of the results of treatment with these drugs and their tolerability and safety within the framework of routine clinical practice. Objective. The aim of the study was to present the experience of the Republic of Tatarstan in the etiopathogenetic therapy of ivacaftor + tezacaftor + elexacaftor and ivacaftor with a change of trade name within the same international nonproprietary name in pediatric patients diagnosed with cystic fibrosis, to demonstrate the clinical efficacy of this drug and its safety Conclusion. During 2025, 80 patients received etiopathogenetic therapy with ivacaftor + tezacaftor + elexacaftor and ivacaftor, including 12 children under 6 years of age, 19 aged 6 to 12 years, and 46 patients aged 12 to 18 years. The average age of patients at the start of therapy was 7.5 years. Patients with the pulmonary-intestinal form of the disease (E 84.8) prevailed – 78.3%, with a predominantly pulmonary form (E 84.0) – 21.7%. Prior to the initiation of targeted therapy and when changing the drug to a triple fixed dose combination, a comprehensive assessment of the functional capabilities of the child's body was carried out within the framework of one international nonproprietary name. Monitoring of the safety and effectiveness of treatment was carried out 14 days after the start of therapy, 1 month after, 3 months after, 6 months after, and 12 months after. Against the background of the three-component targeted therapy, patients showed an improvement in respiratory function (FEV1 and FVC), positive weight and height dynamics. When changing the drug within the same international nonproprietary name , the indicators of the function of external respiration remained at the achieved level. During the 6 months of follow-up, there were no exacerbations of cystic fibrosis that required hospitalization.


  • Study of the efficacy and safety of the generic drug ivacaftor + tezacaftor + elexacaftor/ivacaftor (trade name Trilexa®)

    by E. I. Kondratyeva, A. Yu. Voronkova, I. R. Fatkhullina, A. V. Orlov, O. G. Pyaterkina, T. A. Protasova, O. S. Psyurnikova

    Cystic fibrosis (CF) is a universal exocrine disorder that affects virtually all organs and systems containing exocrine glands. A genetic defect in the cystic fibrosis transmembrane conductance regulator gene leads to increased viscosity of exocrine gland secretions, primarily in the respiratory tract. CFTR modulators improve the synthesis, processing, and/or function of the defective CFTR protein, which is a chloride channel. Objective. To evaluate the efficacy of the generic drug ivacaftor + tezacaftor + elexacaftor/ivacaftor (trade name Trilexa®), in a group of patients not previously receiving triple targeted therapy after 3 months of treatment in patients who have not previously received the first threecomponent CFTR modulator. Methods. Data from the Russian CF Patient Registry, entered into the “Targeted Therapy” block, were analyzed for the period from January to August 2025 (main group) and for the period from January 2022 to August 2022 (comparison group). Two groups of patients were identified: Group 1 included 28 pediatric patients (12 boys/16 girls) with a confirmed diagnosis of cystic fibrosis, who started receiving triple targeted therapy generic drug ivacaftor + tezacaftor + elexacaftor/ivacaftor. Group 2, the comparison group, consisted of 34 pediatric patients (14 boys/20 girls) who started receiving the original triple targeted drug ivacaftor + tezacaftor + elexacaftor/ivacaftor (trade name Trikafta®). Results. When assessing the nutritional status, a significant increase in BMI was shown in both groups of patients at the start and after 3 months; p < 0.001. Sweat test parameters (conductivity in mmol/L) differed significantly both at the start of therapy and after a month in both groups. The difference between the average sweat test values (Δ mmol/L) in both groups were comparable and did not differ from each other. The groups did not differ in the number of adverse events, which were mild and did not lead to drug discontinuation. Both drugs, the original and the generic, demonstrated safety and good tolerability. Group 1 value was 43 (35.5; 55), and Group 2 value was 42 (32; 50.3); p = 0.86. FEV1 and FVC indicators showed a tendency to increase with both drugs, but it was not significant in both groups. Conclusion. The triple targeted therapy with the use of generic drug ivacaftor + tezacaftor + elexacaftor/ivacaftor is effective and safe in this sample of pediatric patients with cystic fibrosis. No significant differences were found between generic drug and the original drug in relation to the main efficacy criteria during 3 months of use. The frequency, spectrum, and severity of reported adverse events associated with the use of generic drug were comparable to those associated with the use of the original drug.


  • Open Access

    Regional experience in monitoring children with cystic fibrosis on targeted therapy in the Republic of Tatarstan

    by O. G. Pyaterkina, O. A. Karpova, G. R. Begieva, I. R. Zinnatullin, I. I. Zakirov

    In connection with the introduction of targeted therapy for cystic fibrosis (CF) into clinical practice, there is a need to study the clinical effectiveness of these drugs and to record their possible side effects in children.The aim was to present the regional experience of the Republic of Tatarstan in the use of etiopathogenetic therapy (ivacaftor + tezacaftor + elexacaftor) in 41 children diagnosed with CF.Methods. Before initiation of triple therapy, a comprehensive assessment of body functions was carried out. Monitoring of safety and effectiveness was carried out at 14 days, 1 month, 3 months, 6 months, and 12 months after from the start of therapy.Results. In the first 2 weeks from the start of therapy, 10 (27%) patients reported mild side effects in the form of increased cough, sputum, and rhinorrhea, 2 (5,4%) patients had skin rashes, and 3 (8,1%) patients had elevated blood aminotransferases. One child developed encephalopathy due to arterial hypertension several months after starting therapy.Conclusion. Monitoring of the safety of the therapy over 12 months in children with CF showed a satisfactory profile. The therapy was associated with an improvement in the body functions, nutritional status, and quality of life.